Finanzen von Eupraxia Pharmaceuticals Inc (EPRX)EPRXEupraxia Pharmaceuticals Inc

Evaluating the bottom line, Eupraxia Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -108.45%, provide a clear picture of how effectively EPRX converts its operational activities into shareholder value.

In the context of the broader market, EPRX competes directly with industry leaders such as WVE and CADL. With a market capitalization of $459.21M, it holds a significant position in the sector. When comparing efficiency, EPRX's gross margin of N/A stands against WVE's 100.00% and CADL's N/A. Such benchmarking helps identify whether Eupraxia Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eupraxia has reported widening net losses, with a net loss of $12.7 million in Q1 2026, up from $6.8 million in Q1 2025. The current ratio remains strong at 16.00, indicating good short-term liquidity despite losses.